REFERENCES
- Burris III HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line ther-apy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
- Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002; 29: 9–16.
- Pelzer U, Stieler J, Roll L et al. Second-line therapy in refractory pancreatic cancer. Results of a phase II study. Onkolo-gie 2009; 32: 99–102.
- Sternberg CN, Sordillo PP, Cheng E, Chuang YJ, Niedzwiecki D . Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. Am J Clin Oncol 1987; 10: 219–221.
- Topham C, Glees J, Rawson NS, Woods EM, Coombes RC. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer 1991; 64: 179–181.
- Wils J, Bleiberg H, Blijham G et al. Phase II study of epiru-bicin in advanced adenocarcinoma of the pancreas. Eur J Can-cer Clin Oncol 1985; 21: 191–194.
- Therasse P, Arbuck SG, Eisenhaur EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2004; 92: 205–216.
- Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147–159.
- Aoki K, Shimada Y, Okazaki N et al. A phase II study of epirubicin in patients with advanced adenocarcinoma of the pan-creas. Eur J Cancer 1992; 28: 1590.
- Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxatin sal-vage chemotherapy in gemcitabine resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785–791.
- Reni M, Cereda S, Passoni P et al. A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarci-noma. Proc Am Soc Clin Oncol 2007; 25: abstract 4628.
- Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
- Reni M, Cordio S, Milandri C et al. Gemcitabine vs cis-platin, epirubicin, fluorouracil, and gemcitabine in advanced pan-creatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369–376.
- Boeck S, Wilkowski R, Bruns CJ et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic can-cer. Oncology 2007; 73: 221–227.
- Cereda S, Ghidini M, Passoni P et al. Salvage therapy with mitomycin and ifosfamide (MI) in patients with gemcitabine-resistant metastatic pancreatic cancer. Ann Oncol 2008; 19: ab-stract 577.